MenABCWY Noninferiority Study in Healthy Participants 10 to <26 Years of Age

  • End date
    Jul 18, 2022
  • participants needed
  • sponsor
Updated on 10 October 2021
Accepts healthy volunteers


The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of MenABCWY and the comparators in both ACWY-nave and ACWY-experienced healthy participants 10 to <26 years of age.

Condition Meningococcal Polysaccharide Vaccine, meningococcal vaccine
Treatment Saline, MenABCWY, MenACWY-CRM, Trumenba
Clinical Study IdentifierNCT04440163
Last Modified on10 October 2021


Yes No Not Sure

Inclusion Criteria

Male or female subject aged >=10 and <26 years at the time of randomization
Healthy subject as determined by medical history, physical examination, and judgment of the investigator
Negative urine pregnancy test for all female subjects
ACWY-nave participants: Participants who have never received a prior dose of a meningococcal vaccine containing ACWY serogroups
ACWY-experienced participants: Participants who have received not more than 1 prior dose, no sooner than 4 years prior to the date of randomization of Menactra or Menveo

Exclusion Criteria

Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide (nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine.- Subjects receiving any allergen immunotherapy with a non-licensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses
A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study
Significant neurological disorder or history of seizure (excluding simple febrile seizure)
Current chronic use of systemic antibiotics
Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 28 days prior to study entry and/or during study participation
Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis
History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae
Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note